• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
MRC Laboratory of Molecular Biology

MRC Laboratory of Molecular Biology

One of the world's leading research institutes, our scientists are working to advance understanding of biological processes at the molecular level - providing the knowledge needed to solve key problems in human health.

  • Home
  • About LMB
  • Research
  • Research Groups
  • Students
  • Recruitment
  • Life at the LMB
  • Achievements
  • News & Events

Insight on Research

Targeting RNA replication in SARS-CoV-2

Published on 3 February, 2021

Chris Russo’s, David Barford’s, Jan Löwe’s, and John Sutherland’s groups have together solved the structure of the inhibitor favipiravir-RTP in complex with the SARS-CoV-2 RNA-dependent RNA polymerase, providing new insight into its mechanism of action.

Furin protease is not essential for SARS-CoV-2 infection

Published on 29 January, 2021

Scientists had thought that the protease furin was responsible for cleavage of the SARS-CoV-2 Spike protein to reveal the fusion machinery that enables infection, but new work from Leo James’ group shows that furin is not essential for SARS-CoV-2 infection.

How the fate of immune cell precursors is decided

Published on 11 January, 2021

Type 2 ILCs (ILC2s) play an important role in dealing with parasites and are implicated in allergy. Andrew McKenzie’s group has discovered that the transcription factor RORα acts as a checkpoint controlling divergence between T cell and ILC2 development.

A new 2D protein material for studying receptor endocytosis

Published on 6 January, 2021

Emmanuel Derivery’s group, in collaboration with David Baker’s group in Seattle, have, for the first time, re-engineered two proteins so that they assemble into a 2D material and used this design to investigate a fundamental process of cell biology, receptor endocytosis.

TRIM21 links antibody and T cell immunity to combat viral infection

Published on 4 December, 2020

Our immune system generates a strong antibody response against nucleoproteins, but the role of this has not been understood. Leo James’ group has revealed a new mechanism that could have important implications for SARS-CoV-2 vaccination and treatment.

First structure of a fungal GPCR

Published on 2 December, 2020

Human GPCRs are the targets of approximately 34% of all FDA-approved drugs. GPCRs in fungi could also be useful drug targets, but no structures of fungal GPCRs had been solved. Chris Tate’s group has now determined the first structure of a fungal GPCR.

  • « Go to Previous Page
  • Page 1
  • Interim pages omitted …
  • Page 18
  • Page 19
  • Page 20
  • Page 21
  • Page 22
  • Interim pages omitted …
  • Page 63
  • Go to Next Page »

Primary Sidebar

Search

  • Privacy & Cookies
  • Contact Directory
  • Freedom of Information
  • Site Map
Find Us
©2025 MRC Laboratory of Molecular Biology,
Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0QH, UK. 01223 267000

The MRC is part of UK Research and Innovation

Contact Us

This site uses cookies. The LMB may use cookies to analyse how you use our website. We use external analysis systems which may set additional cookies to perform their analysis. These cookies (and any others in use) are detailed in our Privacy and Cookies Policy and are integral to our website. You can delete or disable these cookies in your web browser if you wish, but then our site may not work as it is designed.